Organon Q1 2026: Revenue Slide Continues, Biosimilars Shine but Women's Health Weakens

What happened

Organon reported Q1 2026 revenue of $1.460 billion, down 4% reported and 9% constant currency year-over-year, dragged by a 16% reported decline in Women's Health (19% ex-FX) as Nexplanon continued to suffer from reduced U.S. government funding. Biosimilars grew 23% reported (21% ex-FX), providing a partial offset, while Established Brands slipped 1% reported (7% ex-FX). The results confirm the deepening pressure on the core women's health franchise, which had already flagged in 2025, and underscore the critical need for biosimilars and cost discipline to stabilize the top line. Management's earlier 2025 guidance had already implied negative growth, and this quarter suggests the erosion is tracking at the lower end of expectations. For a company carrying over $8 billion in net debt, the deteriorating revenue mix raises the stakes for deleveraging through free cash flow and asset sales like the Jada divestiture.

Implication

The Q1 results reinforce our base case of flattish to declining revenue through 2027, but the sharper-than-expected Women's Health decline increases the probability of the bear scenario (~$6) if biosimilars cannot sustain high-teens growth. We still see asymmetric upside from distressed multiples (~4x EPS, ~6.4x EV/EBITDA) if deleveraging progresses and governance repairs regain credibility, but the path is narrower and requires tighter monitoring of quarterly biosimilar revenue and debt paydown. Position sizing should reflect the higher execution risk; we would re-evaluate if net leverage fails to trend toward 4x by year-end 2026.

Thesis delta

The Q1 2026 results tilt the risk-reward slightly toward the bear case, as Women's Health weakness is proving deeper and more persistent than anticipated. While the master report's base case assumed roughly flat revenue, the 9% ex-FX decline in Q1 suggests revenue may contract low-to-mid single digits in 2026, delaying the stabilization timeline. This raises the required contribution from biosimilars (which must grow >20% to offset erosion) and increases the importance of cost containment and Jada proceeds for debt reduction. We maintain our potential buy rating but with a lower conviction until we see evidence that Women's Health can stabilize in the coming quarters.